Association of Systemic Inflammatory Markers and Clinical Outcomes Among Children With Wilms Tumor
- 11 April 2025
- journal article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (7) , e31715
Abstract
Background: Elevated pre‐treatment inflammatory markers predict disease progression and overall survival among adults with renal tumors, including elevated neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), and lymphocyte‐to‐monocyte ratio (LMR). We hypothesized that elevated inflammatory markers at diagnosis predict higher disease stages and adverse outcomes for children with Wilms tumor. Procedure: We performed a retrospective review of children with Wilms tumor who underwent surgical resection at two centers from 2002 to 2022. Differences in patient demographics and laboratory parameters were compared between the overall disease stages. Differences in tumor characteristics and patient outcomes were compared by elevated LMR, NLR, and PLR at diagnosis using Wilcoxon tests and chi‐squared or Fisher's exact tests. For LMR, NLR, and PLR, optimal cut points for predicting disease ≥ stage 3 were determined using the Youden index for optimization. Results: Data were collected from 235 children with Wilms tumor. The median age was 39.8 months and 50.2% of patients were female; 40 had stage 1 disease, 50 had stage 2 disease, 61 had stage 3 disease, 54 had stage 4 disease, and 26 had stage 5 disease. Preoperative inflammatory markers varied with the overall stage. LMR, NLR, and PLR increased as the stage increased. After controlling for age, final histology, and any abnormal genetic marker, elevated NLR, PLR, and LMR at presentation were each associated with significantly higher odds of stage 3 or 4 disease. Conclusion: Elevation in serum inflammatory markers at diagnosis among children with Wilms tumors is associated with higher disease stage, cancer recurrence, and unfavorable histology.Keywords
This publication has 14 references indexed in Scilit:
- Associations between neutrophil‐to‐lymphocyte ratio and platelet‐to‐lymphocyte ratio and prognosis in patients with neuroblastomaPediatric Blood & Cancer, 2023
- Can Systemic Immune-Inflammation Index Create a New Perspective for the IMDC Scoring System in Patients with Metastatic Renal Cell Carcinoma?Urologia Internationalis, 2021
- The tumor microenvironmentCurrent Biology, 2020
- Prognostic value of neutrophil‐to‐lymphocyte ratio and platelet‐to‐lymphocyte ratio for breast cancer patients: An updated meta‐analysis of 17079 individualsCancer Medicine, 2019
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- Neutrophil-to-lymphocyte Ratio, Platelet-to-lymphocyte Ratio, and C-reactive Protein as New and Simple Prognostic Factors in Patients With Metastatic Renal Cell Cancer Treated With Tyrosine Kinase Inhibitors: A Systemic Review and Meta-analysisClinical Genitourinary Cancer, 2018
- Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumabLung Cancer, 2017
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Cancer-related inflammationNature, 2008
- How can I deal with missing data in my study?Australian and New Zealand Journal of Public Health, 2001